View on GitHub

This release contains 989 approved relationships.

Added entries:

  • (FDA) IDH1 and IDH2 somatic variants and sensitivity to vorasidenib for patients with astrocytoma and oligodendroglioma. Specifically, IDH1 p.R132C, p.R132G, p.R132H, p.R132L, p.R132S, and IDH2 p.R172K and p.172G.
  • (FDA) EGFR p.L858R and exon 19 deletions and sensitivity to lazertinib in combination with amivantamab for patients with non-small cell lung cancer.